Christopher Lee Tompkins

US Patent:

7135314, Nov 14, 2006

Filed:

Apr 17, 1997

Appl. No.:

08/842827

Inventors:

David W. Leung - Mercer Island WA, US
Christopher K. Tompkins - Bothell WA, US

Assignee:

Cell Therapeutics, Inc. - Seattle WA

International Classification:

C12N 9/16
C12N 15/55
C12P 7/64

US Classification:

435134, 435196, 435 41, 435128, 435135, 435147, 435262, 536 232

Abstract:

This invention relates to a biotechnology invention concerning human phosphatidic acid phosphatase. More particularly, this invention relates to three variants of human phosphatidic acid phosphatase namely PAP-α(1 and 2), PAP-β and PAP-γ and uses thereof.

US Patent:

20020169125, Nov 14, 2002

Filed:

Mar 20, 2002

Appl. No.:

10/101487

Inventors:

David Leung - Mercer Island WA, US
Philip Bergman - Mountlake Terrace WA, US
Alan Lofquist - Kirkland WA, US
Gregory Pietz - Seattle WA, US
Christopher Tompkins - Bothell WA, US
David Waggoner - Seattle WA, US

Assignee:

CELL THERAPEUTICS, INC.

International Classification:

A61K038/17
A61K038/18
A61K038/19
A61K038/20
A61K038/21

US Classification:

514/012000, 424/085100, 424/085400, 424/085200, 530/350000, 530/351000, 530/399000, 435/069500, 435/069700

Abstract:

A polyanionic polymer can improve the bioactivity and water-solubility properties of a drug to which it is joined. The inventive method provides a monodispersed preparation of a recombinantly-produced polyanionic polymer that can be easily manipulated, such as lengthened. An active moiety may be chemically or recombinantly joined to a polyanionic polymer to increase its biological half-life and/or solubility. The instant invention also provides a method for targeting the delivery of a polyanionic polymer conjugate or fusion protein to a specific cell type or tissue.

US Patent:

20050118136, Jun 2, 2005

Filed:

Sep 14, 2004

Appl. No.:

10/939988

Inventors:

David Leung - Mercer Island WA, US
Philip Bergman - Mountlake Terrace WA, US
Alan Lofquist - Kirkland WA, US
Gregory Pietz - Seattle WA, US
Christopher Tompkins - Bothell WA, US
David Waggoner - Seattle WA, US

International Classification:

A61K038/20
A61K038/19
A61K038/21
A61K039/395
C07K014/535
C07K014/54

US Classification:

424085100, 424085700, 530351000, 424130100

Abstract:

A polyanionic polymer can improve the bioactivity and water-solubility properties of a drug to which it is joined. The inventive method provides a monodispersed preparation of a recombinantly-produced polyanionic polymer that can be easily manipulated, such as lengthened. An active moiety may be chemically or recombinantly joined to a polyanionic polymer to increase its biological half-life and/or solubility. The instant invention also provides a method for targeting the delivery of a polyanionic polymer conjugate or fusion protein to a specific cell type or tissue.

US Patent:

20080176288, Jul 24, 2008

Filed:

Oct 30, 2007

Appl. No.:

11/928737

Inventors:

David W. Leung - Mercer Island WA, US
Philip A. Bergman - Mountlake Terrace WA, US
Alan Lofquist - Kirkland WA, US
Gregory E. Pietz - Seattle WA, US
Christopher K. Tompkins - Bothell WA, US
David W. Waggoner - Seattle WA, US

International Classification:

C12P 21/00
C07K 1/00
C07K 16/00
C12N 15/64

US Classification:

435 697, 530399, 530351, 5303871, 4353201

Abstract:

A polyanionic polymer can improve the bioactivity and water-solubility properties of a drug to which it is joined. The inventive method provides a monodispersed preparation of a recombinantly-produced polyanionic polymer that can be easily manipulated, such as lengthened. An active moiety may be chemically or recombinantly joined to a polyanionic polymer to increase its biological half-life and/or solubility. The instant invention also provides a method for targeting the delivery of a polyanionic polymer conjugate or fusion protein to a specific cell type or tissue.

US Patent:

62743635, Aug 14, 2001

Filed:

Jun 30, 1998

Appl. No.:

9/107149

Inventors:

David W. Leung - Mercer Island WA
Christopher K. Tompkins - Bothell WA

Assignee:

Cell Therapeutics, Inc. - Seattle WA

International Classification:

C12N 920
C12N 120
C12N 1500
C07H 2104

US Classification:

435198

Abstract:

Three new isoforms of phosphatidylcholine phospholipase D, hPLD2. 1, hPLD2. 2 and hPLD1. 5, can be produced recombinantly and are useful for screening compounds, as drug candidates, for an ability to modify PCPLD activity.

US Patent:

60602635, May 9, 2000

Filed:

Sep 21, 1999

Appl. No.:

9/400742

Inventors:

David W. Leung - Mercer Island WA
James W. West - Seattle WA
Christopher K. Tompkins - Bothell WA

Assignee:

Cell Therapeutics, Inc. - Seattle WA

International Classification:

C12N 910
C12Q 148

US Classification:

435 15

Abstract:

There is disclosed cDNA sequences and polypeptides having the enzyme lysophosphatidic acid acyltransferase (LPAAT) activity. LPAAT is also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.

US Patent:

58592229, Jan 12, 1999

Filed:

Dec 17, 1996

Appl. No.:

8/768147

Inventors:

David W. Leung - Mercer Island WA
Christopher K. Tompkins - Bothell WA

Assignee:

Cell Therapeutics, Inc. - Seattle WA

International Classification:

C07H 2104
C12N 920
C12Q 100
C07K 100

US Classification:

536 232

Abstract:

Disclosed are human cDNA and polypeptides sequences having phosphatidylcholine phospholipase D (PCPLD).

US Patent:

61369640, Oct 24, 2000

Filed:

Mar 19, 1996

Appl. No.:

8/618651

Inventors:

David W. Leung - Mercer Island WA
James W. West - Seattle WA
Christopher K. Tompkins - Bothell WA

Assignee:

Cell Therapeutics, Inc. - Seattle WA

International Classification:

C07H 2104
C12N 910
C12N 912

US Classification:

536 232

Abstract:

There is disclosed cDNA sequences and polypeptides having the enzyme lysophosphatidic acid acyltransferase (LPAAT) activity. LPAAT is also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.